The Joint American Academy of Dermatology and National Psoriasis Foundation Guidelines2 point out the lack of definitive evidence between interleukin (IL)-12/IL-23 and IL-17 inhibitors and solid tumor or lymphoreticular malignancies for psoriasis treatment.2 This evidence concerns the gene IL17A and psoriasis.